Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 5Recruiting 2Completed 2Active not recruiting 2Withdrawn 1No longer available 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × loncastuximab tesirine × Clear all
NCT05144009 2025-01-30

LOTIS-9

ADC Therapeutics S.A.

Phase 2 Terminated
41 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03684694 2024-02-06

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

ADC Therapeutics S.A.

Phase 1/2 Terminated
136 enrolled 33 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04699461 2023-10-23

LOTIS-6

ADC Therapeutics S.A.

Phase 2 Terminated
6 enrolled 9 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

ADC Therapeutics S.A.

Phase 1 Terminated
13 enrolled 15 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02669264 2021-05-24

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

ADC Therapeutics S.A.

Phase 1 Terminated
35 enrolled 31 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡